Mesa Laboratories MLAB Clinical Genomics — Inventory Net
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:InventoryNet.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's clinical genomics — inventory net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's clinical genomics — inventory net?
- Mesa Laboratories (MLAB) reported clinical genomics — inventory net of $8.32M in Q1 2026.
- How has Mesa Laboratories's clinical genomics — inventory net changed year-over-year?
- Mesa Laboratories's clinical genomics — inventory net decreased by 14.9% year-over-year, from $9.78M to $8.32M.
- What is the long-term trend for Mesa Laboratories's clinical genomics — inventory net?
- Over 2 years (2023 to 2026), Mesa Laboratories's clinical genomics — inventory net has grown at a -18.1% compound annual growth rate (CAGR), from $53.89M to $36.18M.
- What does clinical genomics — inventory net mean?
- Represents the net value of inventory held by the Clinical Genomics segment after accounting for reserves, obsolescence, and write-downs. This metric reflects the capital tied up in raw materials, work-in-progress, and finished goods specifically for genetic analysis tools. Monitoring this helps assess inventory turnover efficiency and potential risks of product obsolescence in a high-tech manufacturing environment.